<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 06 Apr 2021 07:24:27 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>小分子药物的困境与出路</title><link>https://mp.weixin.qq.com/s/chgUWeUnNrNrwr1eaZCwPw</link><description></description><content:encoded><![CDATA[小分子药物的困境与出路]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>CDE：ADC药物PK研究要点</title><link>https://mp.weixin.qq.com/s/oORWE9owDyNXJk9srSdQrA</link><description></description><content:encoded><![CDATA[CDE：ADC药物PK研究要点]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>化学原料药杂质研究与控制策略</title><link>https://mp.weixin.qq.com/s/_13n3hi470v568AD0UaZjQ</link><description></description><content:encoded><![CDATA[化学原料药杂质研究与控制策略]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>梳理 | 2类创新药行业报告汇总</title><link>https://mp.weixin.qq.com/s/zm2Bsa9TrDppMa7bkq79Mg</link><description></description><content:encoded><![CDATA[梳理 | 2类创新药行业报告汇总]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>药物制剂中药物与辅料相互作用的研究进展</title><link>https://mp.weixin.qq.com/s/2TvdzetzsI8BqO9HejJbFA</link><description></description><content:encoded><![CDATA[药物制剂中药物与辅料相互作用的研究进展]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>国内外吸入剂BE研究要点分析</title><link>https://mp.weixin.qq.com/s/GG8osueSKdlEJzbrXAKGMA</link><description></description><content:encoded><![CDATA[国内外吸入剂BE研究要点分析]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>CDE解答124个技术问题</title><link>https://mp.weixin.qq.com/s/g0B_j4Ph9C5ug42YBjU79A</link><description></description><content:encoded><![CDATA[CDE解答124个技术问题]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item><item><title>刚刚！CDE发布纳米药物3大指导原则！纳米药物质量控制、非临床安评、非临床药代动力学！</title><link>https://mp.weixin.qq.com/s/kJZT4zVuIFW3Qymsd9sEJw</link><description></description><content:encoded><![CDATA[刚刚！CDE发布纳米药物3大指导原则！纳米药物质量控制、非临床安评、非临床药代动力学！]]></content:encoded><pubDate>Wed, 31 Mar 2021 20:58:03 +0800</pubDate></item><item><title>杂质研究与控制 —基本思路与策略</title><link>https://mp.weixin.qq.com/s/MtBcGFKuqlck0aYYOb0EQw</link><description></description><content:encoded><![CDATA[杂质研究与控制 —基本思路与策略]]></content:encoded><pubDate>Wed, 31 Mar 2021 20:58:03 +0800</pubDate></item><item><title>质量人必备的14张图，赶紧收藏！</title><link>https://mp.weixin.qq.com/s/X59_TR4SN78qo98tWfjbyQ</link><description></description><content:encoded><![CDATA[质量人必备的14张图，赶紧收藏！]]></content:encoded><pubDate>Wed, 31 Mar 2021 20:58:03 +0800</pubDate></item><item><title>化学药物生产现场检查问答总结</title><link>https://mp.weixin.qq.com/s/CihbWH7WPPi38LuRE0nv_w</link><description></description><content:encoded><![CDATA[化学药物生产现场检查问答总结]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:48:17 +0800</pubDate></item><item><title>全球首个BCMA CAR-T疗法获批上市！治疗多发性骨髓瘤</title><link>https://mp.weixin.qq.com/s/dPLYmHIr5DgVXyuLw1DJug</link><description></description><content:encoded><![CDATA[全球首个BCMA CAR-T疗法获批上市！治疗多发性骨髓瘤]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:48:17 +0800</pubDate></item><item><title>聚焦小分子创新药FIC，罗氏/海思科/恒瑞/交大/复旦...PharmaCon首批嘉宾阵容曝光</title><link>https://mp.weixin.qq.com/s/t3_PSlQ9p0_R-mLSMmB4-A</link><description></description><content:encoded><![CDATA[聚焦小分子创新药FIC，罗氏/海思科/恒瑞/交大/复旦...PharmaCon首批嘉宾阵容曝光]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:48:17 +0800</pubDate></item><item><title>对&#34;生产工艺变更”那些有的没的...</title><link>https://mp.weixin.qq.com/s/uZNbgLRWw63Ab2sNZg8mRA</link><description></description><content:encoded><![CDATA[对"生产工艺变更”那些有的没的...]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:48:17 +0800</pubDate></item><item><title>药物免疫原性研究技术指导原则</title><link>https://mp.weixin.qq.com/s/ILvq3RsCIdFICRO_mX9YKw</link><description></description><content:encoded><![CDATA[药物免疫原性研究技术指导原则]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:39:39 +0800</pubDate></item><item><title>FDA培训PPT： 工艺验证与ICHQ7</title><link>https://mp.weixin.qq.com/s/8GRS5Y4Cpi_jnjz1iQ_NQQ</link><description></description><content:encoded><![CDATA[FDA培训PPT： 工艺验证与ICHQ7]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:39:39 +0800</pubDate></item><item><title>一图看懂康龙化成2020年年报</title><link>https://mp.weixin.qq.com/s/TCHbXZnxXchzhXnKxQJZ9A</link><description></description><content:encoded><![CDATA[一图看懂康龙化成2020年年报]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:39:39 +0800</pubDate></item><item><title>集采迫近！生物类似药该怎样与原研“争雄天下”？</title><link>https://mp.weixin.qq.com/s/0hAx2s61xu-2DQrtReehwA</link><description></description><content:encoded><![CDATA[集采迫近！生物类似药该怎样与原研“争雄天下”？]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:39:39 +0800</pubDate></item><item><title>严重副作用不同疾病的对应手册（面向患者·公众）（60）-周围神经病变</title><link>https://mp.weixin.qq.com/s/T03A1fmFJH1hSaTgNLXA-Q</link><description></description><content:encoded><![CDATA[严重副作用不同疾病的对应手册（面向患者·公众）（60）-周围神经病变]]></content:encoded><pubDate>Sun, 28 Mar 2021 19:53:11 +0800</pubDate></item><item><title>药品专利期限补偿制度红利能否惠及已上市新药引关注专家建议</title><link>https://mp.weixin.qq.com/s/o2hnd8YYu4U4wjIzl6Ss0g</link><description></description><content:encoded><![CDATA[药品专利期限补偿制度红利能否惠及已上市新药引关注专家建议]]></content:encoded><pubDate>Sun, 28 Mar 2021 19:53:11 +0800</pubDate></item></channel></rss>